AstraZeneca to buy US firm ZS Pharma for $2.7bn

Drug giant AstraZeneca has agreed to buy US firm ZS Pharma in a $2.7bn (€2.5bn) cash deal.

AstraZeneca to buy US firm ZS Pharma for $2.7bn

It will give UK-based AstraZeneca access to a drug that could potentially treat life-threatening condition, hyperkalaemia.

The drug, ZS-9, is currently under regulatory review by the US Food and Drug Administration.

Already a subscriber? Sign in

You have reached your article limit.

Unlimited access. Half the price.

Annual €120 €60

Best value

Monthly €10€5 / month

More in this section

The Business Hub

Newsletter

News and analysis on business, money and jobs from Munster and beyond by our expert team of business writers.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited